Skip to main content
$150.81 $1.70 (1.1%)

12:31 PM EDT on 05/25/22

AbbVie Inc. (NYSE:ABBV)

CAPS Rating: 4 out of 5

Current Price $150.81 Mkt Cap $263.5B
Open $150.36 P/E Ratio 21.28
Prev. Close $149.11 Div. (Yield) $5.64 (3.8%)
Daily Range $149.79 - $152.99 Volume 1,816,374
52-Wk Range $105.56 - $175.91 Avg. Daily Vol. 7,697,803

Caps

How do you think NYSE:ABBV will perform against the market?

Add Stock to CAPS Watchlist

All Players

640 Outperform
13 Underperform
 

All-Star Players

110 Outperform
3 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NYSE:ABBV Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

JohnnyCaffeine (< 20)
Submitted January 13, 2022

Good new drugs coming on line to replace the profits that came from Humira

TMFSpiffyPop (99.71)
Submitted January 09, 2015

This mega-cap has made a big run since Express Scripts's announcement that it will take AbbVie's hep C treatment in lieu of Gilead's. Also, an amazing preponderance of CAPS bulls favor this stock beating the market from here -- very interesting. For… More

NYSE:ABBV VS S&P 500 (SPY)

Fools bullish on NYSE:ABBV are also bullish on:

Fools bearish on NYSE:ABBV are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about ABBV.

Recs

0
Member Avatar TMFWordman5150 (24.86) Submitted: 2/17/2022 12:04:57 PM : Outperform Start Price: $143.78 NYSE:ABBV Score: +15.57

Earnings Growth; a solid dividend of $5.64 per share; and a Pharma manufact. market with a CAGR of 11.34% through 2028.

Recs

1
Member Avatar JohnnyCaffeine (< 20) Submitted: 1/13/2022 6:48:34 AM : Outperform Start Price: $133.86 NYSE:ABBV Score: +29.32

Good new drugs coming on line to replace the profits that came from Humira

Recs

1
Member Avatar TMFkodyk123 (70.96) Submitted: 7/26/2021 12:53:49 PM : Outperform Start Price: $115.32 NYSE:ABBV Score: +41.34

Despite AbbVie's near-term headwinds relating to the upcoming loss of exclusivity of Humira in the U.S., the company boasts promising drugs in its oncology and immunology segments. Venclexta has 3 different indications that are anticipated to be approved by next year. In addition, the stock appears to be trading at a discount to fair value with an attractive 4.4% dividend yield.

Leaderboard

Find the members with the highest scoring picks in ABBV.

Score Leader

concealedweaponR

concealedweaponR (< 20) Score: +386.50

The Score Leader is the player with the highest score across all their picks in ABBV.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
armydave 48.46 1/10/2013 12/6/2017 Outperform 5Y $23.06 +555.99% +169.49% +386.50 0 Comment
pirotta < 20 1/10/2013 Outperform 5Y $23.06 +555.99% +169.49% +386.50 0 Comment
deliman723 67.47 1/10/2013 Outperform 5Y $23.06 +555.99% +169.49% +386.50 0 Comment
concealedweaponR < 20 1/10/2013 Outperform 5Y $23.06 +555.99% +169.49% +386.50 0 Comment
drjohn432 < 20 1/10/2013 10/25/2020 Outperform 5Y $23.06 +555.99% +169.49% +386.50 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. valari25 99.70 1/10/2013 9/2/2020 Outperform 5Y $23.06 +555.99% +169.49% +386.50 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. GW1000 85.68 1/10/2013 7/6/2018 Outperform 5Y $23.06 +555.99% +169.49% +386.50 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. mattmmurphy 72.51 1/10/2013 Outperform 5Y $23.06 +555.99% +169.49% +386.50 0 Comment
cooleyly 59.85 1/10/2013 Outperform 5Y $23.06 +555.99% +169.49% +386.50 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. kinosternon 98.81 1/9/2013 Outperform 5Y $23.17 +553.02% +170.74% +382.28 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for ABBV.